Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma 
Welcome,         Profile    Billing    Logout  

6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Panzyga (human immune globulin intravenous 10% stabilised with glycine) / Octapharma
NCT03866798 / 2019-004063-49: Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

Active, not recruiting
4
20
US
Panzyga
Octapharma
Chronic Immune Thrombocytopenia
04/24
04/24
2019-004375-40: Study for the evaluatiion of Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study) Studie zur Ermittlung der Wirksamkeit und Sicherheit von Panzyga in der primären Infektionsprophylaxe bei Patienten mit chronischer lymphatischer Leukämie ("PRO-SID"-Studie)

Not yet recruiting
3
450
Europe, RoW
Panzyga, [NA], Solution for infusion, Panzyga
Octapharma Pharmazeutika Produktionsges.m.b.H., OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H., Octapharma Pharmazeutika Produktionsges.m.b.H.
Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia, Prophylaxis to prevent infection in patients with a type of cancer that starts in bone marrow and then go into the blood, Diseases [C] - Cancer [C04]
 
 
PROSID, NCT04502030: Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)

Recruiting
3
240
Europe, US, RoW
Panzyga, Placebo
Octapharma
Chronic Lymphocytic Leukemia, Hypogammaglobulinemia
10/25
10/25
NGAM-13, NCT04508530 / 2020-000867-21: Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS)

Active, not recruiting
3
70
Europe, US
Panzyga, Placebo
Octapharma
Pediatric Acute-Onset Neuropsychiatric Syndrome
06/24
06/24
NGAM-11, NCT04929236 / 2021-003200-40: Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Recruiting
3
30
US
Panzyga
Octapharma
Pediatric Chronic Inflammatory Demyelinating Polyneuropathy
06/26
06/26
NCT04153422: IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies

Recruiting
2
20
US
Panzyga IVIG, Placebo
Henry Ford Health System, Octapharma USA, Inc.
Small Fiber Neuropathy, Autoimmune Small Fiber Neuropathy, Inflammatory Polyneuropathy, Immune-Mediated Neuropathy
12/26
04/27

Download Options